Company intelligence / Profile preview

NINER

Dubai, Dubai, United Arab Emirates

Ownership: Private
Development stage: Other

Overview

Niner Pharma manufactures high-purity peptides (99%), runs vertically-integrated operations from API to finished formulations, and supplies IV fluids and vaccines. US market entry is underway, with regulatory processes and strategic partnerships pending. The company is recognized for large-scale manufacturing and aims to alleviate supply shortages and improve quality standards in new regions

Therapeutic areas: OncologyInfectious DiseasesOther
Modalities: Small moleculePeptidesVaccinesGeneric drugsSpecialty medications
Industry: Biotech

Partnerships

Partnerships with hospitals in the US, Latin America, Europe, GCCstrategic distribution partners (specific names pending)

Beyond the preview

Go deeper on NINER.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NINER.

Explore the full profile